Hypoadiponectinemia: A Link between Visceral Obesity and Metabolic Syndrome

Table 1

Principal metabolic syndrome definitions.

	WHO (1999)	EGIR (1999)	NCEP ATP III (2001)
Fasting plasma glucose	Glucose intolerance, IGT or diabetes, and/or insulin resistance together with two or more of the following:	Insulin resistance (defined as hyperinsulinemia—top 25% or fasting insulin values among the nondiabetic population). Plus two of the following:	3 or more of the following factors:
		≥6.1 mmol/L (110 mg/dl) but nondiabetic	5.6 mmol/L (100 mg/dl)
Blood pressure	>140/90 mmHg	≥140/90 mmHg or treatment	≥130/≥ 85 mmHg
Triglycerides	Raised plasma triglycerides; ≥1.7 mmol/L (150 mg/dl); and/or	(i) 2.0 mmol/L (178 mg/dl) or treatment and/or	1.7 mmol/L (150 mg/dl)
HDL-cholesterol	Men: <0.9 mmol/L (35 mg/dl) Women: <1.0 mmol/L (39 mg/dl)	<1.0 mmol/L (39 mg/dl) or treatment	Men: <1.03 mmol/L (40 mg/dl); Women: <1.29 mmol/L (50 mg/dl)
Obesity	Men: waist-hip ratio >0.90; Women: waist-hip ratio >0.85; and/or BMI >30 Kg/^2	Men: waist circumference ≥ 94 cm Women: waist circumference ≥80 cm	Men: waist circumference >102 cm; Women waist circumference >88 cm
Microalbuminuria	Urinary albumin excretion rate; ≥ 20 𝜇g/min or albumin: creatinine ratio ≥30 mg/g

WHO:World Health Organization; EGIR: European Group for the Study of Insulin Resistance; NCEP/ATPIII: National Cholesterol Education Program's Adult Treatment Panel III.